c.v. for the post of quality assurance RamanGupta
•Download as DOC, PDF•
4 likes•3,037 views
Raman Gupta is seeking a position that allows him to utilize his 2.9 years of professional experience in quality assurance and production roles at pharmaceutical companies. He has a B.Pharm degree with 73.6% marks and worked in quality assurance at Ravian Lifesciences and in production at Cotac Health Care. His responsibilities included quality control processes, documentation, validation work, and using SAP and LIMS systems. He is proficient in MS Office and several quality and regulatory standards.
Report
Share
Report
Share
Recommended
Resume- SEP16
Kavita Sharma is seeking a challenging role in quality assurance for a pharmaceutical organization. She has over 8 years of experience in quality assurance roles. She has a B.Pharmacy degree with 76% and a D.Pharmacy degree with 70%. Her experience includes regulatory audits from organizations like USFDA, MHRA, and ANVISA. She has worked at Akorn India as a Senior Executive in QA Training since 2016 and previously worked at Sentiss Pharma as Senior Executive in Production from 2008 to 2016. Her responsibilities included training management, quality management systems, managing an IPQA team, documentation, and batch release. She has knowledge in areas like batch manufacturing, autoclaving, CIP/SIP
Sikanders resume in - Copy
Sikander is applying for a position and has over 5 years of experience in quality assurance for formulations like injectables, tablets, capsules and pellets. He currently works as an Associate in Quality Assurance at Dr. Reddy's Laboratories in Hyderabad, India. He has a B-Pharmacy degree and believes his qualifications are a good fit for the requirements of the position.
ISO series, guide of pharmaceutical manufacturing facilities, productivity b...
The document summarizes key aspects of ISO standards for quality management systems, including ISO 9000 and ISO 14000. It discusses the history and development of ISO standards, an overview of the ISO 9000 series, and highlights of the ISO 9000:2000 standard. The presentation focuses on process-based quality management and continual improvement as core principles of the ISO standards.
Out of specification shravan
An out of specification (OOS) occurs when analytical results fall outside established specification ranges. There are guidelines from organizations like MHRA, CDER, and PIC/S for handling OOS events. OOS can occur during stability studies, finished products, or raw materials due to laboratory errors, process issues, or sample homogeneity problems. Investigations follow a phased approach starting with the quality control laboratory and then involving manufacturing operations if needed. The fate of an OOS batch may include reprocessing, reworking, or destruction depending on the investigation conclusions.
Pharmaceutical Quality Management System
According to new syllabus of PCI M.Pharm 1st sem. students can directly utilize this ppt for their study. As per PCI new syllabus QA STUDENTS find this ppt very use full.
Regulated and Non-Regulated marked
M.Pharm 1st year, Quality Assurance Department, Quality Control Quality Assurance, Concept of Reulatory & Non-Regulatory Markets in Pharma industry
Pharmaceutical process validation.pptx
The document discusses pharmaceutical process validation. It defines validation as proving a process consistently produces quality products. There are three main types of validation: prospective validation done before use, retrospective using historical data, and concurrent during routine production. Validation ensures quality, reduces costs, and meets regulations. It involves qualification of facilities and equipment, then protocols to test processes over multiple batches and demonstrate control. Periodic revalidation is also required when changes are made.
Content and format of dossier filling in india
This document provides an overview of the dossier submission process for drug approval. It discusses the Common Technical Document (CTD) format adopted by the Central Drugs Standard Control Organization of India based on International Conference on Harmonization guidelines. The CTD format organizes the dossier into five modules containing administrative information, quality data, nonclinical studies, clinical studies and references. Compliance with the CTD format and inclusion of all required information is necessary for regulatory approval of new drugs.
Recommended
Resume- SEP16
Kavita Sharma is seeking a challenging role in quality assurance for a pharmaceutical organization. She has over 8 years of experience in quality assurance roles. She has a B.Pharmacy degree with 76% and a D.Pharmacy degree with 70%. Her experience includes regulatory audits from organizations like USFDA, MHRA, and ANVISA. She has worked at Akorn India as a Senior Executive in QA Training since 2016 and previously worked at Sentiss Pharma as Senior Executive in Production from 2008 to 2016. Her responsibilities included training management, quality management systems, managing an IPQA team, documentation, and batch release. She has knowledge in areas like batch manufacturing, autoclaving, CIP/SIP
Sikanders resume in - Copy
Sikander is applying for a position and has over 5 years of experience in quality assurance for formulations like injectables, tablets, capsules and pellets. He currently works as an Associate in Quality Assurance at Dr. Reddy's Laboratories in Hyderabad, India. He has a B-Pharmacy degree and believes his qualifications are a good fit for the requirements of the position.
ISO series, guide of pharmaceutical manufacturing facilities, productivity b...
The document summarizes key aspects of ISO standards for quality management systems, including ISO 9000 and ISO 14000. It discusses the history and development of ISO standards, an overview of the ISO 9000 series, and highlights of the ISO 9000:2000 standard. The presentation focuses on process-based quality management and continual improvement as core principles of the ISO standards.
Out of specification shravan
An out of specification (OOS) occurs when analytical results fall outside established specification ranges. There are guidelines from organizations like MHRA, CDER, and PIC/S for handling OOS events. OOS can occur during stability studies, finished products, or raw materials due to laboratory errors, process issues, or sample homogeneity problems. Investigations follow a phased approach starting with the quality control laboratory and then involving manufacturing operations if needed. The fate of an OOS batch may include reprocessing, reworking, or destruction depending on the investigation conclusions.
Pharmaceutical Quality Management System
According to new syllabus of PCI M.Pharm 1st sem. students can directly utilize this ppt for their study. As per PCI new syllabus QA STUDENTS find this ppt very use full.
Regulated and Non-Regulated marked
M.Pharm 1st year, Quality Assurance Department, Quality Control Quality Assurance, Concept of Reulatory & Non-Regulatory Markets in Pharma industry
Pharmaceutical process validation.pptx
The document discusses pharmaceutical process validation. It defines validation as proving a process consistently produces quality products. There are three main types of validation: prospective validation done before use, retrospective using historical data, and concurrent during routine production. Validation ensures quality, reduces costs, and meets regulations. It involves qualification of facilities and equipment, then protocols to test processes over multiple batches and demonstrate control. Periodic revalidation is also required when changes are made.
Content and format of dossier filling in india
This document provides an overview of the dossier submission process for drug approval. It discusses the Common Technical Document (CTD) format adopted by the Central Drugs Standard Control Organization of India based on International Conference on Harmonization guidelines. The CTD format organizes the dossier into five modules containing administrative information, quality data, nonclinical studies, clinical studies and references. Compliance with the CTD format and inclusion of all required information is necessary for regulatory approval of new drugs.
Out of specifications (oos)
The document provides guidelines for handling out of specification test results as outlined by the USFDA. It defines an out of specification result as one that falls outside the defined test limits. It discusses the USFDA's OOS guidelines published in 2006 and notes that quality units should have a defined SOP for addressing OOS results. The SOP scope should be well defined and investigations into OOS results should be thorough, timely, unbiased, well documented, and scientifically sound. Laboratory investigations should check for errors and, if none are found, a phase II investigation including retesting and investigation at the plant may be initiated. Tools like 5M, 5 whys, DMAIC and root cause analysis should be used to identify
Ipqc
This document provides information about in-process quality control (IPQC) for a student named Pournima Ashok guided by Mrs. M. Harde. It defines IPQC as checks performed during production to monitor and adjust the process to ensure the product meets specifications. This may include controlling the environment or equipment. IPQC is intended to minimize errors, provide accurate procedures, detect errors, allow for corrective actions, identify responsibilities, and enforce established manufacturing and packing operations. Examples of IPQC for tablets include testing for container content uniformity, active ingredient content, tablet thickness, hardness, friability, and disintegration. Friability testing evaluates the tendency of tablets to fragment or powder during storage and handling.
Roshan (1)
This document provides information about the US Food and Drug Administration (FDA). It describes the organization and responsibilities of the FDA, including protecting public health by regulating food, drugs, medical devices, and other products. It also summarizes key FDA centers like the Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. The document introduces the Pharmaceutical Inspection Convention, its objectives to harmonize good manufacturing practices among countries.
Pharmaceutical Qualification & Validation
Qualification and Validation have big Weightage in the Regulatory Compliance and GMP. Qualification and Validation only can guarantee about the Product Safety, Integrity, Strength, Purity and Quality assurance.
Emea
The document discusses the European Medicines Agency (EMEA), which is responsible for evaluating and supervising medicines in the European Union. It describes the various committees within EMEA, including the Committee for Medicinal Products for Human Use (CHMP) which authorizes medicines, the Committee for Orphan Medicinal Products (COMP) which designates orphan drugs for rare diseases, and others focused on veterinary medicines, herbal medicines, and pharmaceutical regulation. The EMEA ensures that authorized medicines meet quality, safety, and efficacy standards and monitors medicines once they reach the market.
Vendor qualification
This document discusses vendor certification and categorization. It defines vendor certification as ensuring a vendor will meet regulatory expectations. Vendors are categorized from 1 to 4 based on risk, with category 1 being experts with minimal monitoring and category 4 being sole-source API manufacturers requiring intense monitoring. The document also outlines the vendor qualification process, including selection criteria, evaluation of production processes, and standard procedures for quality audits.
Vendor qualification
This document provides information about vendor qualification procedures in the pharmaceutical industry. It begins with definitions of key terms like vendor and qualification. It then describes the types of vendors, including business-to-business and business-to-customer. It outlines a classification system for vendors from Category 1 to 4 based on risk. The document details the seven steps for vendor selection and qualification procedures for raw material and packaging material vendors. It provides guidance on inclusion of vendors in the approved vendor list and reasons for exclusion from the list, along with corrective actions.
Basic concepts of QA and QC
Quality assurance and quality control are important concepts in pharmaceutical manufacturing. Quality assurance refers to planned and systematic activities that ensure quality in processes, while quality control refers to activities that ensure quality in products. Some key differences are that quality assurance focuses on preventing defects through proper processes, while quality control identifies defects in finished products. Total quality management aims to produce perfect products through quality measures at every stage of production and requires team effort across an organization.
Quality by Design
This document discusses the new quality paradigm in pharmaceuticals which emphasizes building quality in from the beginning through a systematic quality by design (QbD) approach. It outlines the key elements of QbD including establishing a quality target product profile, identifying critical quality attributes, understanding material attributes and process parameters that impact critical quality attributes through risk assessment, developing a design space, and implementing a control strategy. The new paradigm focuses on science-based approaches, quality risk management, robust quality systems, and an integrated approach across the product lifecycle between industry and regulators.
C gmp0
Current Good Manufacturing Practices (cGMP) are followed by pharmaceutical and biotechnology companies
Items are manufactured to specific requirements including identity, strength, quality, and purity. Good Manufacturing Practices are regulated by the Food and Drug Administration (FDA)
IND, NDA, ANDA, SNDA
The document discusses Investigational New Drug Applications (INDs), New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and Supplemental New Drug Applications (SNDAs). It provides details on the purpose and requirements of each application type, including necessary contents, guidelines, and the laws and regulations that govern the FDA drug approval process.
Quality Risk Management
This document discusses quality risk management (QRM) in the pharmaceutical industry. It begins by introducing QRM and its importance in ensuring quality systems. The document then outlines the scope of QRM, including its application across various stages of drug development and manufacturing. The core principles and process of QRM are described, including risk assessment, control, communication, and review. Various risk management tools are also introduced. Finally, the document discusses integrating QRM into industry and regulatory operations to facilitate consistent decision making.
Dossier preparation and submission
This document discusses dossier preparation and submission for regulatory approval of pharmaceutical products. It defines a dossier as a collection of documents on a subject used to propose approval of a new drug. Dossiers contain administrative, quality, nonclinical, and clinical data. Common dossier formats include CTD, ACTD, and eCTD, which are used globally and in various regions. Careful compilation, review, and planning is required to ensure dossiers meet all regulatory requirements for submission.
CHANGE CONTROL
The document discusses a proposed change in the coating process for Dapakan 500mg film coated tablets from a solvent coating to an aqueous coating. It describes changing from coating with Opadry OIC 7000 to coating with Opadry II. A risk assessment is proposed to evaluate any changes in color, weight gain, thickness or process validation needs. The impact on materials management, quality control, quality assurance, production and regulatory requirements is evaluated. References from regulatory bodies on quality guidelines and GMP are also provided.
Process validation ppt.
This document discusses process validation in the pharmaceutical industry. It defines process validation and describes it as having three stages: process design, process qualification, and continued process verification. The objectives and requirements of each stage are explained. Process validation helps ensure a process consistently produces products meeting specifications and quality attributes. It involves understanding and controlling sources of variation. Validation protocols, reports, teams, and the lifecycle are also reviewed to explain how process validation is planned and documented.
Six system inspection model
The document discusses quality management systems and the six system inspection model used by the FDA to ensure compliance with cGMP regulations. It describes each of the six systems - quality system, production system, facilities and equipment system, laboratory control system, materials system, and packaging and labeling system. For each system, it provides an overview and lists the relevant cGMP subparts that govern inspections of that system. The goal is to help pharmaceutical manufacturers implement quality systems to meet FDA requirements.
Analytical method transfer
This document discusses analytical method transfer between laboratories. It defines analytical method transfer as qualifying a receiving laboratory to use a test procedure that originated in another laboratory. There are different types of method transfers, including comparative testing between laboratories, covalidation where both laboratories participate in validation, and complete or partial revalidation of methods in the receiving laboratory. Successful method transfers require several key elements, such as a pre-approved transfer plan, detailed description of test methods and procedures, description of test requirements, rationale for test parameters, acceptance criteria, and documentation of results. The goal is to verify that analytical methods produce equivalent results in different laboratories.
US FDA post approval changes
The document discusses post-approval changes that can be made to approved NDAs and ANDAs. It describes four reporting categories for post-approval changes based on their potential impact: major changes requiring prior approval, moderate changes reported via a CBE-30 or CBE-0 supplement, minor changes reported annually. Examples are provided for different types of changes that fall under each reporting category. The levels of reporting ensure that manufacturers can make certain changes while providing appropriate notification to the FDA depending on the level of change.
Developing specifications q3 q6
This document provides guidelines for developing specifications for new drug substances and products according to ICH Q6A. It discusses universal and specific tests/criteria that should be included for drug substances and products, such as identification, description, assay, impurities, dissolution, disintegration, content uniformity, and microbial limits. The document gives acceptance criteria and justification for key tests like dissolution, discussing how to set Q values and limits based on biobatch results and BCS classification. It also provides guidance on other tests for oral liquids, parenterals and solid dosage forms.
Snda
The document discusses guidelines for supplemental new drug applications (sNDAs) according to the US FDA. It outlines three categories of variations - major, moderate, and minor - based on their potential impact. Major changes require prior approval and could impact safety or efficacy. Moderate changes require submission 30 days before distribution or upon FDA receipt. Minor changes only require description in the annual report. The document provides examples of changes in manufacturing sites, processes, specifications, container closure systems, and labeling that would fall under each category. Close monitoring and reporting of any post-approval changes is recommended to ensure the quality, safety and efficacy of pre-qualified products are not adversely affected.
kanan k
Gandhiji is seeking a position that utilizes his 12 years of experience in pharmaceutical production and quality assurance. He currently works as an Assistant Manager of Production at Medopharm in Chennai, where he oversees tablet and capsule manufacturing, implements lean manufacturing techniques, and ensures documentation compliance. Previously, he held production roles at multiple companies and has experience with equipment qualification and validation as well as developing training programs.
UPDATED CV EXP
The document is a curriculum vitae for Ashish Shukla that summarizes his educational qualifications and professional experience. It includes details about his B. Pharm and M. Pharm degrees, work as a Research Executive at Lupin Ltd., skills in HPLC, FTIR, and other analytical techniques. His objective is to contribute to the pharmaceutical industry and academia through hard work and learning.
More Related Content
What's hot
Out of specifications (oos)
The document provides guidelines for handling out of specification test results as outlined by the USFDA. It defines an out of specification result as one that falls outside the defined test limits. It discusses the USFDA's OOS guidelines published in 2006 and notes that quality units should have a defined SOP for addressing OOS results. The SOP scope should be well defined and investigations into OOS results should be thorough, timely, unbiased, well documented, and scientifically sound. Laboratory investigations should check for errors and, if none are found, a phase II investigation including retesting and investigation at the plant may be initiated. Tools like 5M, 5 whys, DMAIC and root cause analysis should be used to identify
Ipqc
This document provides information about in-process quality control (IPQC) for a student named Pournima Ashok guided by Mrs. M. Harde. It defines IPQC as checks performed during production to monitor and adjust the process to ensure the product meets specifications. This may include controlling the environment or equipment. IPQC is intended to minimize errors, provide accurate procedures, detect errors, allow for corrective actions, identify responsibilities, and enforce established manufacturing and packing operations. Examples of IPQC for tablets include testing for container content uniformity, active ingredient content, tablet thickness, hardness, friability, and disintegration. Friability testing evaluates the tendency of tablets to fragment or powder during storage and handling.
Roshan (1)
This document provides information about the US Food and Drug Administration (FDA). It describes the organization and responsibilities of the FDA, including protecting public health by regulating food, drugs, medical devices, and other products. It also summarizes key FDA centers like the Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. The document introduces the Pharmaceutical Inspection Convention, its objectives to harmonize good manufacturing practices among countries.
Pharmaceutical Qualification & Validation
Qualification and Validation have big Weightage in the Regulatory Compliance and GMP. Qualification and Validation only can guarantee about the Product Safety, Integrity, Strength, Purity and Quality assurance.
Emea
The document discusses the European Medicines Agency (EMEA), which is responsible for evaluating and supervising medicines in the European Union. It describes the various committees within EMEA, including the Committee for Medicinal Products for Human Use (CHMP) which authorizes medicines, the Committee for Orphan Medicinal Products (COMP) which designates orphan drugs for rare diseases, and others focused on veterinary medicines, herbal medicines, and pharmaceutical regulation. The EMEA ensures that authorized medicines meet quality, safety, and efficacy standards and monitors medicines once they reach the market.
Vendor qualification
This document discusses vendor certification and categorization. It defines vendor certification as ensuring a vendor will meet regulatory expectations. Vendors are categorized from 1 to 4 based on risk, with category 1 being experts with minimal monitoring and category 4 being sole-source API manufacturers requiring intense monitoring. The document also outlines the vendor qualification process, including selection criteria, evaluation of production processes, and standard procedures for quality audits.
Vendor qualification
This document provides information about vendor qualification procedures in the pharmaceutical industry. It begins with definitions of key terms like vendor and qualification. It then describes the types of vendors, including business-to-business and business-to-customer. It outlines a classification system for vendors from Category 1 to 4 based on risk. The document details the seven steps for vendor selection and qualification procedures for raw material and packaging material vendors. It provides guidance on inclusion of vendors in the approved vendor list and reasons for exclusion from the list, along with corrective actions.
Basic concepts of QA and QC
Quality assurance and quality control are important concepts in pharmaceutical manufacturing. Quality assurance refers to planned and systematic activities that ensure quality in processes, while quality control refers to activities that ensure quality in products. Some key differences are that quality assurance focuses on preventing defects through proper processes, while quality control identifies defects in finished products. Total quality management aims to produce perfect products through quality measures at every stage of production and requires team effort across an organization.
Quality by Design
This document discusses the new quality paradigm in pharmaceuticals which emphasizes building quality in from the beginning through a systematic quality by design (QbD) approach. It outlines the key elements of QbD including establishing a quality target product profile, identifying critical quality attributes, understanding material attributes and process parameters that impact critical quality attributes through risk assessment, developing a design space, and implementing a control strategy. The new paradigm focuses on science-based approaches, quality risk management, robust quality systems, and an integrated approach across the product lifecycle between industry and regulators.
C gmp0
Current Good Manufacturing Practices (cGMP) are followed by pharmaceutical and biotechnology companies
Items are manufactured to specific requirements including identity, strength, quality, and purity. Good Manufacturing Practices are regulated by the Food and Drug Administration (FDA)
IND, NDA, ANDA, SNDA
The document discusses Investigational New Drug Applications (INDs), New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and Supplemental New Drug Applications (SNDAs). It provides details on the purpose and requirements of each application type, including necessary contents, guidelines, and the laws and regulations that govern the FDA drug approval process.
Quality Risk Management
This document discusses quality risk management (QRM) in the pharmaceutical industry. It begins by introducing QRM and its importance in ensuring quality systems. The document then outlines the scope of QRM, including its application across various stages of drug development and manufacturing. The core principles and process of QRM are described, including risk assessment, control, communication, and review. Various risk management tools are also introduced. Finally, the document discusses integrating QRM into industry and regulatory operations to facilitate consistent decision making.
Dossier preparation and submission
This document discusses dossier preparation and submission for regulatory approval of pharmaceutical products. It defines a dossier as a collection of documents on a subject used to propose approval of a new drug. Dossiers contain administrative, quality, nonclinical, and clinical data. Common dossier formats include CTD, ACTD, and eCTD, which are used globally and in various regions. Careful compilation, review, and planning is required to ensure dossiers meet all regulatory requirements for submission.
CHANGE CONTROL
The document discusses a proposed change in the coating process for Dapakan 500mg film coated tablets from a solvent coating to an aqueous coating. It describes changing from coating with Opadry OIC 7000 to coating with Opadry II. A risk assessment is proposed to evaluate any changes in color, weight gain, thickness or process validation needs. The impact on materials management, quality control, quality assurance, production and regulatory requirements is evaluated. References from regulatory bodies on quality guidelines and GMP are also provided.
Process validation ppt.
This document discusses process validation in the pharmaceutical industry. It defines process validation and describes it as having three stages: process design, process qualification, and continued process verification. The objectives and requirements of each stage are explained. Process validation helps ensure a process consistently produces products meeting specifications and quality attributes. It involves understanding and controlling sources of variation. Validation protocols, reports, teams, and the lifecycle are also reviewed to explain how process validation is planned and documented.
Six system inspection model
The document discusses quality management systems and the six system inspection model used by the FDA to ensure compliance with cGMP regulations. It describes each of the six systems - quality system, production system, facilities and equipment system, laboratory control system, materials system, and packaging and labeling system. For each system, it provides an overview and lists the relevant cGMP subparts that govern inspections of that system. The goal is to help pharmaceutical manufacturers implement quality systems to meet FDA requirements.
Analytical method transfer
This document discusses analytical method transfer between laboratories. It defines analytical method transfer as qualifying a receiving laboratory to use a test procedure that originated in another laboratory. There are different types of method transfers, including comparative testing between laboratories, covalidation where both laboratories participate in validation, and complete or partial revalidation of methods in the receiving laboratory. Successful method transfers require several key elements, such as a pre-approved transfer plan, detailed description of test methods and procedures, description of test requirements, rationale for test parameters, acceptance criteria, and documentation of results. The goal is to verify that analytical methods produce equivalent results in different laboratories.
US FDA post approval changes
The document discusses post-approval changes that can be made to approved NDAs and ANDAs. It describes four reporting categories for post-approval changes based on their potential impact: major changes requiring prior approval, moderate changes reported via a CBE-30 or CBE-0 supplement, minor changes reported annually. Examples are provided for different types of changes that fall under each reporting category. The levels of reporting ensure that manufacturers can make certain changes while providing appropriate notification to the FDA depending on the level of change.
Developing specifications q3 q6
This document provides guidelines for developing specifications for new drug substances and products according to ICH Q6A. It discusses universal and specific tests/criteria that should be included for drug substances and products, such as identification, description, assay, impurities, dissolution, disintegration, content uniformity, and microbial limits. The document gives acceptance criteria and justification for key tests like dissolution, discussing how to set Q values and limits based on biobatch results and BCS classification. It also provides guidance on other tests for oral liquids, parenterals and solid dosage forms.
Snda
The document discusses guidelines for supplemental new drug applications (sNDAs) according to the US FDA. It outlines three categories of variations - major, moderate, and minor - based on their potential impact. Major changes require prior approval and could impact safety or efficacy. Moderate changes require submission 30 days before distribution or upon FDA receipt. Minor changes only require description in the annual report. The document provides examples of changes in manufacturing sites, processes, specifications, container closure systems, and labeling that would fall under each category. Close monitoring and reporting of any post-approval changes is recommended to ensure the quality, safety and efficacy of pre-qualified products are not adversely affected.
What's hot (20)
Similar to c.v. for the post of quality assurance RamanGupta
kanan k
Gandhiji is seeking a position that utilizes his 12 years of experience in pharmaceutical production and quality assurance. He currently works as an Assistant Manager of Production at Medopharm in Chennai, where he oversees tablet and capsule manufacturing, implements lean manufacturing techniques, and ensures documentation compliance. Previously, he held production roles at multiple companies and has experience with equipment qualification and validation as well as developing training programs.
UPDATED CV EXP
The document is a curriculum vitae for Ashish Shukla that summarizes his educational qualifications and professional experience. It includes details about his B. Pharm and M. Pharm degrees, work as a Research Executive at Lupin Ltd., skills in HPLC, FTIR, and other analytical techniques. His objective is to contribute to the pharmaceutical industry and academia through hard work and learning.
Vinay's Resume
Vinay Kumar is seeking a challenging career in a progressive organization where he can utilize his 5+ years of experience in quality assurance for oral solid dosage forms for regulated markets. He has experience reviewing quality incidents and conducting investigations, handling product quality reviews, ensuring GMP compliance, and authoring investigation reports. Vinay Kumar held positions at Dr. Reddy's Laboratories, Mylan Laboratories, and Arvind Remedies where he was responsible for tasks like batch record reviews, audit preparations, training programs, and automation of production processes. He has a Master's degree in Pharmacy from Vel's University and a Bachelor's degree from HITS College of Pharmacy.
Resume
This curriculum vitae summarizes the qualifications and experience of Meduri Seshaiah. He has over 7 years of experience in quality assurance and quality control, currently working as an Assistant Manager for QA & QC. He holds a Master's degree in Organic Chemistry and has worked for various companies, ensuring regulatory compliance and implementation of quality management systems like GMP, ISO and HACCP. He is proficient in analytical techniques like spectroscopy, chromatography and feed analysis parameters. He is seeking a challenging position that allows him to further develop his problem-solving and technical skills.
cv[2]
Shikha Sharma is applying for a QA Officer position. She has over 2 years of experience in quality assurance documentation and has worked at Zeiss Pharma and Scott-Edil Advance Research Laboratories. She has experience with quality management systems, audits, stability studies, and other QA responsibilities. She is seeking a role where she can continue learning and applying her skills in quality assurance.
Mayank Upadhyay - CV 01-July-2015 Updated.
This resume summarizes Mayank Shekhar Upadhyay's career experience and qualifications. He has over 2 years of experience working in drug formulation and regulatory affairs roles for Sun Pharmaceutical and MDC Exports. He holds an M.Pharma in Pharmaceutics from Rajiv Academy For Pharmacy and a B.Pharma from IIMT College of Pharmacy. He is a registered pharmacist and life member of IPGA with expertise in preparing and submitting drug dossiers for international markets. His objective is to utilize his skills in a challenging role that provides learning opportunities to help achieve organizational goals.
Navin Kumar .mgr
This document is a resume for Navin Kumar, who has an MSc in Organic Chemistry. It provides details about his education, work experience, skills, and objectives. Navin has over 11 years of experience in quality assurance roles for pharmaceutical companies. He is currently working as the Manager of Quality Assurance at Midas Care Pharmaceuticals, where he is responsible for audit compliance, corrective action monitoring, and overseeing quality assurance activities. Prior to this, he held quality assurance positions at several other pharmaceutical manufacturers, where his responsibilities included ensuring compliance with cGMP standards, auditing, training, and monitoring quality systems.
Sandeep Kumar Gupta Presentation
Sandeep Kumar Gupta is seeking a dynamic and challenging opportunity as a Senior Officer in quality assurance and quality control with over 4 years of experience in the pharmaceutical industry. He has worked at Akums Drugs & Pharmaceutical Ltd. since 2013 as Senior Officer of QA and at Rivpra Formulation Pvt. Ltd from 2011-2013 as QA Officer. Gupta received his M.Pharma in Pharmaceutical Chemistry from Shobhit University in 2011 and B.Pharma from Uttar Pradesh Technical University in 2009. His skills include good communication, a positive attitude, and the ability to achieve results.
SUMAN_PAL
Suman Pal is applying for a Quality Assurance role. He has over 9 years of experience in quality control and assurance, currently working as a Senior Executive in QA at Fresenius Kabi Oncology Ltd. He has a Postgraduate degree in organic Chemistry and experience with analytical testing, method validation, change management systems and ensuring GMP compliance. He believes his experience and skills are a good fit for the role.
SHIVPAL
Shivpal Baghel is seeking a position that utilizes his skills and promotes professional development. He has over 4 years of experience as a Quality Incharge in the biscuit industry. Currently, he works at Graintech Foods India Pvt. Ltd. ensuring product quality, food safety, and compliance with standards. His responsibilities include quality control, audits, customer complaint resolution, and staff training. He holds a B.Sc. and has experience operating laboratory instruments and conducting analyses.
Curriculum Vitae 2016
This curriculum vitae is for Sanjay Narayan Nalage seeking an Assistant Manager position with experience in quality control for pharmaceuticals. He has a M.Sc. in Biochemistry and B.Sc. in Chemistry from Shivaji University in India. Currently he works as an Executive Quality Control at Emcure Pharmaceuticals with over 13 years of experience previously working at USV Limited. His responsibilities include overseeing day-to-day quality control activities, executing analytical activities, implementing cGMP compliance, and authoring standard operating procedures and documentation. He has expertise in analytical method validation, transfer, and qualification of instruments such as UPLC, HPLC, GC, and UV-VIS spectrophotometers.
CV for Sep, 2015 updated
PVRSN Reddy is seeking a position in quality control and has over 11 years of experience in the role. He holds a BSc from Andhra University and MSc from MKU. Reddy's career history includes positions as Quality Control Incharge at three different pharmaceutical companies between 2007-2015. He has professional skills in instrumentation, chemical analysis, method validation, and document control. Reddy is approved to conduct chemical and instrumentation analysis by the Directorate of Drugs Control Administration in Andhra Pradesh. His areas of experience include quality control, quality assurance, and production processes for tablets, capsules and pellets.
CV-Saurabh
Saurabh Agrawal is seeking an opportunity in regulatory affairs. He has over 3 years of experience in regulatory affairs consulting and as a regulatory executive. His experience includes new drug approvals, medical device and drug registrations, import/export licenses, and compiling drug dossiers for international markets like Myanmar, Cambodia, and others. He has a M.Pharm degree and B.Pharm degree and is computer proficient in Microsoft Office programs.
Uday
Udayveer Singh is applying for a job opening at the company. He has a background in pharmacy and believes his experience is a good fit for the position. He has worked as an Officer-QA at Concept Pharmaceutical Ltd since 2013 where he performed quality assurance tasks like instrument handling, production monitoring, and document review. He is an experienced, excellent communicator and quick learner seeking to contribute his skills.
Resume_Prushin Thakore
Prushin Mananbhai Thakore is seeking a position that allows him to help an organization grow while further developing his own skills and knowledge. He has over 2.7 years of experience working in regulatory affairs at Claris Injectables Limited. His responsibilities include preparing and maintaining regulatory documentation for product submissions and registrations in various countries, communicating with partners, and reviewing technical documents to ensure compliance. Prushin holds an M.Pharm in Pharmacology with 2 years of relevant work experience and is interested in continuing his career in regulatory affairs.
Dilip Davhare CV
(1) Mr. Dilip Ramdas Davhare is seeking a position where he can contribute to an organization's growth using his analytical and regulatory skills. (2) He has over 3 years of experience in analytical method development and validation for pharmaceutical formulations at Cliantha Research and Alembic Pharmaceuticals. (3) His educational background includes an M.Pharmacy in Pharmaceutical Chemistry and a B.Pharmacy degree.
Resume_final
1) Abhradeep Saha is seeking a career opportunity to contribute in the pharmaceutical field with dedicated people to fully explore his potential.
2) He has over 5 years of experience working in process development and formulation technology transfer roles at Mylan Laboratories and Torrent Pharmaceuticals.
3) His experience includes overseeing engineering batches, optimization, validation, technology transfers, and ensuring compliance and smooth production operations.
Resume- Nitin Kumar
Nitin Kumar is a laboratory technician and research manager with over 10 years of experience in the pharmaceutical industry. He has worked at Sun Pharma, one of the largest pharmaceutical companies in the world, and has experience with method validation, technology transfer, and ensuring regulatory compliance. He is skilled in analytical testing, laboratory procedures, and handling analytical instruments such as HPLC. Currently he is working as a Research Manager at Sun Pharmaceutical Industries Limited where he leads various tasks including analytical method validation and technology transfer.
ranjan 3 current
V. Priyaranjan Rao is applying for a postgraduate position in organic chemistry. He has 9 years of experience working in quality control for pharmaceutical companies. He is currently a senior executive at Aurobindo Pharma Ltd. where he performs various quality control functions like instrument calibration, stability sample analysis, and ensuring compliance with CGMP, GLP, ICH, and regulatory guidelines. He is proficient in several analytical instruments and has experience with regulatory audits from agencies like USFDA, WHO, and COFEPRIS. He is seeking a new opportunity to further his career and contribute to an organization with his skills and experience in quality control for the pharmaceutical industry.
ranjan 3 current
V. Priyaranjan Rao is applying for a postgraduate position in organic chemistry. He has 9 years of experience working in quality control for pharmaceutical companies. He is currently a senior executive at Aurobindo Pharma Ltd. where he performs various quality control functions like instrument calibration, stability sample analysis, and ensuring compliance with CGMP, GLP, ICH, USFDA, and other regulatory guidelines. He is seeking a new opportunity to further his career and contribute to the upliftment of an organization with his skills and experience in the pharmaceutical industry.
Similar to c.v. for the post of quality assurance RamanGupta (20)
c.v. for the post of quality assurance RamanGupta
- 1. RESUME Raman Gupta Postal Address: H.NO. 397, Civil Lines Colony, Balrampur- 271201 Mobile: 09759708593 Email: ramangpt14@gmail.com CAREER OBJECTIVE To work in an environment, which provides me chance to sharpen my acquired skills and contribute positively in the progress of organization with paramount results. PROFESSIONAL EXPERIENCE (2.9 YEAR) • Presently working in AKUMS Drugs and Pharmaceutical (Plant No. 6 MAXCURE) Haridwar from 15 th March.2013 to till date. • Worked in Q.A. department at Ravian Lifesciences Haridwar, from Dec. 2012 to March.2013. • Worked in production department in oral solid dosage form at Cotac Health Care, Roorkee from June 2012 to Dec. 2012 EDUCATION QUALIFICATION Completed B. Pharm from Uttar Pradesh Technical University, U.P. with 73.6 percent marks. H.S.C. and S.S.C. completed from ICSE and ISC board, Delhi with 61% & 73.2 percent marks respectively. JOB RESPONSIBILITIES IPQA Activities for Tablet, Capsules (Hard Gel & Soft Gel), Powder, Oral Liquid, Semi Solid Dosage Form- Certify line clearance for various activities as per current SOPs. Check and verify the process control parameters during manufacturing, packing of pharmaceuticals products. Carry out sampling of Bulk, Semi Finished and Finished product as per SOPs. Handling of NCR, Deviations and change Controls. Calibration of Weighing Balances, Disintegration apparatus, Roche Friability apparatus etc. SAP Activities Process Order Approval Result Data Updation and Release of batches to FG store through SAP System.
- 2. Documentation Worked in validation team Equipment qualification and preparation of DQ, IQ, OQ, PQ protocols and report. Thermal and humidity mapping of area and deciding of hot zone in area. Preparation of Protocol for Process Validation and their Report, Preparation of APQR Regulatory Status of Current Plant NSF (USA), FSSAI, ISO 9001:2008, GMP, QMS (HACCP) Audits Faced TEVA, Merck, Dr. Reddy’s , GSK, Torrent, Alkem, Piramal Phytocare NSF (USA), Computer Skills Proficient in using Operating Systems and programs like MS Office, SAP, Oasis LIMS Personal Details Name : Raman Gupta DOB : 14- June-1987 Sex : Male I Raman Gupta hereby declare that all the information provided in my resume is true to the best of my knowledge. Date: Yours Sincerely Place: Raman Gupta